Skip to main content
Transgene logo

Transgene — Investor Relations & Filings

Ticker · TNG ISIN · FR0005175080 LEI · 969500PDJW8N0FSGGK69 PA Professional, scientific and technical activities
Open in API
Filings indexed 796 across all filing types
Latest filing 2022-05-10 Interim / Quarterly Rep…
Country FR France
Listing PA TNG

About Transgene

https://www.transgene.fr/en/

Transgene is a clinical-stage biotechnology company that designs and develops immunotherapies for the treatment of cancer. The company's strategy is based on two proprietary technology platforms. The myvac® platform is used to create individualized neoantigen therapeutic vaccines, such as its clinical candidate TG4050, which leverages advanced genetic engineering and artificial intelligence. The invir.IO® platform is dedicated to developing innovative, multifunctional oncolytic viruses engineered to directly destroy cancer cells and modulate the tumor microenvironment, thereby enhancing the patient's immune response against the tumor.

Recent filings

Filing Released Lang Actions
Quarterly financial reporting / First quarter financial report
Interim / Quarterly Report Classification · 1% confidence The document is a quarterly business update from Transgene for the period ended March 31, 2022. It contains specific financial data (operating revenue, cash position, and net cash burn) and detailed operational updates on clinical trials and corporate governance. While it is a quarterly update, it is not a full interim financial report (which would be more comprehensive and formal). It functions as a management-led update on business performance and financial status for the quarter, fitting the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. Q1 2022
2022-05-10 English
Information financière trimestrielle / Information financière du premier trimestre
Interim / Quarterly Report Classification · 1% confidence The document is a quarterly business and financial update from Transgene (TNG) for the first quarter of 2022. It contains specific financial data (operating income, cash position) and detailed operational updates on clinical trials and governance. It is not a full annual report (10-K) nor a simple announcement of a report (RPA), but rather a substantive interim financial and operational update, which fits the definition of an Interim/Quarterly Report (IR). Q1 2022
2022-05-10 French
Inside Information / Other news releases
Earnings Release Classification · 1% confidence The document is a press release announcing positive preliminary clinical data for a drug candidate (TG4050) to be presented at the American Association for Cancer Research (AACR) 2022 meeting. It details clinical trial progress, immunological data, and mentions preclinical data for another product (BT-001). This type of announcement, focusing on research updates, trial results, and upcoming presentations, is characteristic of an Earnings Release (ER) or a general Investor Presentation (IP) if it were a slide deck. However, since it is a formal press release detailing financial/operational updates (clinical trial progress, safety data) that are not the full quarterly/annual report, and it is not explicitly a presentation or a transcript, it fits best as an Earnings Release (ER) which often includes operational highlights, or potentially an Investor Presentation (IP) if the focus was purely strategic. Given the structure—key highlights followed by detailed updates on ongoing trials—it functions as a primary release of operational/clinical performance data. Since it is not a comprehensive quarterly report (IR) or a formal presentation (IP), and it is a release of results, ER is the most appropriate fit among the options, although it is heavily focused on R&D progress rather than standard financial metrics. It is not a proxy statement (PSI), management discussion (MDA), or a formal regulatory filing (RNS) for a specific event like a dividend or share change. It is a release of performance information. FY 2022
2022-04-08 English
Informations privilégiées / Autres communiqués
Earnings Release Classification · 1% confidence The document is a press release dated April 8, 2022, announcing 'nouvelles données préliminaires de Phase I' (new preliminary Phase I data) regarding the clinical trial progress of TG4050, which will be presented at the AACR 2022 congress. It details clinical activity, immunogenicity results, safety profiles, and provides specific poster presentation details (Title, Number, Date/Time/Location). This format—a formal announcement of results that are being presented elsewhere (like a conference) or released shortly after—is characteristic of an Earnings Release (ER) or a general announcement. Since it focuses on the release of new clinical trial results and key highlights rather than being a comprehensive periodic report (like 10-K or IR), 'ER' (Earnings Release) is the most appropriate classification, as clinical trial updates often serve as the primary 'results' announcement for biotech firms outside of standard financial reporting periods. It is not a full transcript (CT), a formal annual report (10-K), or a simple notice of report publication (RPA), as it contains substantial substantive data. FY 2022
2022-04-08 French
Rapports financiers et d'audit annuels / Rapport financier annuel
Annual Report Classification · 1% confidence The document is a 'Document d'enregistrement universel' (Universal Registration Document) for the fiscal year 2021, which explicitly includes the annual financial report. In the European regulatory context, this document serves as the equivalent of an Annual Report (10-K equivalent), containing audited financial statements, management reports, governance information, and risk factors. It is a comprehensive annual disclosure document rather than a simple announcement or a quarterly report. FY 2021
2022-04-07 French
Terms of availability of a registration document or its updates
Report Publication Announcement Classification · 1% confidence The document is a short press release announcing the availability of the '2021 Universal Registration Document' which was submitted to the AMF. It explicitly states that the document is available on the company website and the AMF website. According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement stating that a report has been published or is available elsewhere should be classified as a Report Publication Announcement (RPA). The document itself is not the full Universal Registration Document (which would likely be classified as 10-K or IR, depending on jurisdiction/content), but rather the notice of its publication.
2022-04-07 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.